Details for New Drug Application (NDA): 062167
✉ Email this page to a colleague
NDA 062167 describes BACITRACIN-NEOMYCIN-POLYMYXIN, which is a drug marketed by Pharmaderm, Altana, and Padagis Us, and is included in three NDAs. Additional details are available on the BACITRACIN-NEOMYCIN-POLYMYXIN profile page.
The generic ingredient in BACITRACIN-NEOMYCIN-POLYMYXIN is bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate profile page.
The generic ingredient in BACITRACIN-NEOMYCIN-POLYMYXIN is bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate profile page.
Summary for 062167
| Tradename: | BACITRACIN-NEOMYCIN-POLYMYXIN |
| Applicant: | Pharmaderm |
| Ingredient: | bacitracin zinc; neomycin sulfate; polymyxin b sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | OINTMENT;OPHTHALMIC | Strength | 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
